drugset / Trial / NCT06547164

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

NCT06547164

Phase 1 Completed 40 enrolled AstraZeneca
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will be conducted in order to determine the effect of repeated oral doses of camizestrant on the pharmacokinetics (PK) of midazolam and to determine the effect of repeated oral titrated doses of carbamazepine on the PK of camizestrant in healthy post-menopausal female participants.

Timeline

Start
2024-08-27
Primary completion
2025-08-20
Completion
2025-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Camizestrant Other / unclassified Oral
Subject Carbamazepine Small molecule Oral
Subject Midazolam Small molecule Oral

Indications

No indication recorded.